Quantitative analysis for Opus Genetics, Inc. (IRD) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (51.0) (grade C). Gem alpha score: 40.0. 31 signals analyzed (26 differentiated alt-data).
IRD stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-30 | $5.23 | $4.70 | $5.11 |
| 2026-05-12 | $5.20 | $4.95 | $5.18 |
| 2026-05-22 | $4.38 | $4.19 | $4.26 |
| 2026-06-04 | $4.68 | $4.20 | $4.64 |
| 2026-06-16 | $3.98 | $3.80 | $3.90 |
| 2026-06-29 | $4.18 | $3.97 | $4.06 |
| 2026-07-10 | $4.02 | $3.84 | $3.92 |
| 2026-07-22 | $3.10 | $3.00 | $3.05 |
| 2026-08-03 | $3.79 | $3.54 | $3.64 |
| 2026-08-13 | $3.87 | $3.70 | $3.72 |
| 2026-08-25 | $4.42 | $4.04 | $4.11 |
| 2026-09-04 | $4.80 | $4.40 | $4.67 |
How Opus Genetics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| SNDL | SNDL Inc. | $373M | — |
| KYTX | Kyverna Therapeutics, Inc. | $375M | 38.0 |
| SY | So-Young International Inc. | $346M | 65.0 |
| CABA | Cabaletta Bio, Inc. | $331M | — |
View all Health Care stocks by valuation and signals →
Opus Genetics, Inc. (IRD) scores Hold (51.0), and the composite conceals a 95-point disagreement between its dimensions. It is strongest on ML forecast at 96 and earnings quality at 82, and weakest on AI Alpha (gem) at 23 and competitive moat at 1. A stock can carry ML forecast that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 96 |
| earnings quality | 82 |
| analyst consensus | 82 |
| valuation | 72 |
| technicals | 34 |
| AI Alpha (gem) | 23 |
| competitive moat | 1 |
StoQuant analyzes 31 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Opus Genetics, Inc. (IRD): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IRD"><img src="https://stoquant.com/badge/IRD.svg" alt="Opus Genetics, Inc. (IRD) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.